These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21222548)

  • 1. Crystalline form of a neutrophil elastase inhibitor, 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide p-toluene sulfonate - is it AZD-9668?: WO-2010094964.
    Norman P
    Expert Opin Ther Pat; 2011 Feb; 21(2):277-80. PubMed ID: 21222548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase.
    Stevens T; Ekholm K; Gränse M; Lindahl M; Kozma V; Jungar C; Ottosson T; Falk-Håkansson H; Churg A; Wright JL; Lal H; Sanfridson A
    J Pharmacol Exp Ther; 2011 Oct; 339(1):313-20. PubMed ID: 21791628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
    Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
    Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423).
    Norman P
    Expert Opin Ther Pat; 2013 Sep; 23(9):1239-45. PubMed ID: 23865465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857.
    Norman P
    Expert Opin Ther Pat; 2009 Aug; 19(8):1165-8. PubMed ID: 19505194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which of three structures is AZD-3199? WO-2008104790, WO-2008096112 and WO-2008096119.
    Norman P
    Expert Opin Ther Pat; 2009 Aug; 19(8):1157-63. PubMed ID: 19563269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence on the identity of the CXCR2 antagonist AZD-5069.
    Norman P
    Expert Opin Ther Pat; 2013 Jan; 23(1):113-7. PubMed ID: 22992174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors.
    Sjö P
    Future Med Chem; 2012 Apr; 4(5):651-60. PubMed ID: 22458683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.
    von Nussbaum F; Li VM; Allerheiligen S; Anlauf S; Bärfacker L; Bechem M; Delbeck M; Fitzgerald MF; Gerisch M; Gielen-Haertwig H; Haning H; Karthaus D; Lang D; Lustig K; Meibom D; Mittendorf J; Rosentreter U; Schäfer M; Schäfer S; Schamberger J; Telan LA; Tersteegen A
    ChemMedChem; 2015 Jul; 10(7):1163-73. PubMed ID: 26083237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).
    Tsai YF; Hwang TL
    Expert Opin Ther Pat; 2015; 25(10):1145-58. PubMed ID: 26118988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool.
    Shimamura K; Kitazawa H; Miyamoto Y; Kanesaka M; Nagumo A; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
    J Pharmacol Exp Ther; 2009 Jul; 330(1):249-56. PubMed ID: 19359527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.
    Norman P
    Expert Opin Ther Pat; 2015 Apr; 25(4):493-9. PubMed ID: 25623274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Quan ML; Han Q; Galemmo RA; Amparo E; Wells B; Ellis C; He MY; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; Mersinger L; Kettner C; Bai S; He K; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4141-7. PubMed ID: 16730984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115?
    Norman P
    Expert Opin Ther Pat; 2012 Nov; 22(11):1377-83. PubMed ID: 22917191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples.
    Gu C; Lewis RJ; Wells AS; Svensson PH; Hosagrahara VP; Johnsson E; Hallström G
    Drug Metab Dispos; 2015 Oct; 43(10):1441-9. PubMed ID: 26203069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924.
    Saulnier MG; Frennesson DB; Wittman MD; Zimmermann K; Velaparthi U; Langley DR; Struzynski C; Sang X; Carboni J; Li A; Greer A; Yang Z; Balimane P; Gottardis M; Attar R; Vyas D
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1702-7. PubMed ID: 18258427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
    Lucas SD; Gonçalves LM; Carvalho LA; Correia HF; Da Costa EM; Guedes RA; Moreira R; Guedes RC
    J Med Chem; 2013 Dec; 56(23):9802-6. PubMed ID: 24224573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of 1-Methyl-N-(propan-2-yl)-N-({2-[4-(trifluoromethoxy)phenyl]pyridin-4-yl}methyl)-1H-imidazole-4-carboxamide as a Potent and Orally Available Glycine Transporter 1 Inhibitor.
    Yamamoto S; Ohta H; Abe K; Kambe D; Tsukiyama N; Kawakita Y; Moriya M; Yasuhara A
    Chem Pharm Bull (Tokyo); 2016; 64(11):1630-1640. PubMed ID: 27803474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil elastase inhibitors.
    Groutas WC; Dou D; Alliston KR
    Expert Opin Ther Pat; 2011 Mar; 21(3):339-54. PubMed ID: 21235378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
    J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.